Study to Evaluate LPH-5 in Healthy Subjects
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexMale
Age18-65
SponsorLophora
About this trial
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.
Eligibility criteria
Qualifiers
Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, and clinical laboratory evaluations.
Disqualifiers
Any condition or disease detected during the medical interview/physical examination that could relapse during or immediately after the study, or would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the clinical study, as determined by the Investigator.
Have a history of and/or current clinically significant determined by the Investigator
Consumes cannabis or cannabis-derived compounds more than 3 times per month or has substantial changes in cannabis consumption in the 21 days prior to screening.
Trial design
Treatments tested in this trial
- LPH-5
- Placebo
Treatment groups
48 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Locations
Sponsors and collaborators
Lophora
Lead sponsor
Biotrial
Collaborator
Source ClinicalTrials.gov